Shared on06 Aug 25Fair value Increased 6.38%
Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33. What's in the News Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 99%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 53.2x to 58.8x.
Shared on02 Apr 25Fair value Increased 85%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 47%
AnalystConsensusTarget has decreased profit margin from 12.3% to 10.5% and increased future PE multiple from 65.6x to 76.4x.